AI Consensus Investment Thesis
CRISPR Therapeutics (CRSP) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
NEUTRAL$63
+11.1%5-Year
BUY$109
+92.6%Latest flagship insight
Gene Editing Leader Pivots From Commercial Gestation To In Vivo Platform Compounding
High consensus confirms Casgevy commercial cash flow will steadily offset corporate research expenditures through expanding treatment centers. However, long-term valuation hinges on whether wholly owned in vivo clinical pipelines successfully navigate Phase 2 trials without encountering off-target genomic toxicity or onerous financing dilution.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
J.P. Morgan (Titan), Warren Buffett (Value Purist), Ray Dalio (Strategist), Michael Burry (Vulture), Universal Investor (Polymath), Machiavelli (Insider), Elon Musk (Visionary), Sherlock Holmes (Whistleblower), Superintelligence (Anthropologist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in CRISPR Therapeutics at the forecast anchor (2026-09-18): $19,260 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 58.12 | +2.76% | +2.76% | Commercial patient apheresis starts expand across authorized treatment centers, driving modest revenue gains. However, macroeconomic duration pressures and lingering skepticism regarding autologous cell processing cycle times keep valuation gains measured. |
| Q1 2027 | 58.73 | +1.06% | +3.84% | Full-year reporting exposes the divergence between partner gross therapy sales and recognized collaboration income. Net operating losses remain substantial as clinical research outlays across wholly owned pipelines absorb early commercial royalty inflows. |
| Q2 2027 | 60.53 | +3.06% | +7.02% | Pediatric label expansion conversions and finalized European reimbursement frameworks expand treatment center throughput. Operational absorption improves, allowing collaboration expense deductions to stabilize while cash burn trends moderately lower. |
| Q3 2027 | 62.84 | +3.82% | +11.11% | Presentation of mid-stage durability data for the hepatic lipid editing program demonstrates sustained biomarker knockdown. Investors begin re-evaluating the platform beyond rare hematology, lifting trading multiples despite tight broader monetary conditions. |
| Q4 2027 | 65.29 | +3.90% | +15.44% | Portfolio digestion and year-end rebalancing induce mild multiple compression. Markets weigh expanding clinical development commitments against ongoing autologous manufacturing bottlenecks, prompting tactical consolidation around baseline balance sheet cash support. |
| Q1 2028 | 66.36 | +1.64% | +17.33% | Pediatric infusion volume gains across North America improve commercial program cash generation. Vertex collaboration receipts begin visibly dampening corporate cash burn, reinforcing investor confidence in balance sheet durability. |
| Q2 2028 | 70.00 | +5.48% | +23.76% | Advancement of wholly owned in vivo assets into larger clinical cohorts drives pipeline valuation gains. Steady commercial revenue execution counters broader macroeconomic tightness, supporting constructive institutional accumulation. |
| Q3 2028 | 72.36 | +3.37% | +27.94% | Casgevy achieves operational cash breakeven within the joint collaboration structure. The removal of partnership cash drag allows non-dilutive balance sheet interest income to effectively buffer internal clinical research expenditures. |
| Q4 2028 | 74.61 | +3.11% | +31.92% | Increased clinical spending required for concurrent Phase 2 cardiometabolic trials temporarily widens quarterly net losses. Investors balance the heavy investment intensity against encouraging long-term pipeline biomarker durability. |
| Q1 2029 | 77.14 | +3.39% | +36.39% | Annual financial results demonstrate sustained reduction in operating cash burn as global commercial therapy adoption broadens. Long-term fundamental value seekers accumulate shares, recognizing the transition toward commercial self-funding. |
| Q2 2029 | 80.50 | +4.36% | +42.33% | Potential non-dilutive licensing arrangements or co-development partnerships for wholly owned clinical assets inject fresh balance sheet capital. Strategic optionality validates proprietary lipid nanoparticle delivery platforms across cardiometabolic cohorts. |
| Q3 2029 | 83.24 | +3.40% | +47.17% | International reimbursement milestones across mature markets deliver stable recurring royalty distributions. The stock demonstrates resilient relative performance as research automation and clinical prioritization optimize operational productivity. |
| Q4 2029 | 86.71 | +4.17% | +53.30% | Clinical progression in allogeneic immunology programs demonstrates multi-disease platform utility. Steady commercial execution offsets minor sector multiple compression stemming from persistent high risk-free interest rates. |
| Q1 2030 | 90.10 | +3.91% | +59.29% | Casgevy collaboration cash flow reaches meaningful operational contribution, fully funding corporate general overhead. Institutional growth capital reweights toward the equity as commercial longevity dispels early adoption skepticism. |
| Q2 2030 | 91.86 | +1.96% | +62.42% | Registration-enabling clinical data for proprietary hepatic editing programs approach completion. The prospect of broad cardiometabolic market access expands forward enterprise value multiples across Wall Street models. |
| Q3 2030 | 95.91 | +4.41% | +69.58% | Commercial cell therapy reaches mature steady-state adoption in Western jurisdictions. Steady cash distributions provide a dependable fundamental floor while investors await registrational filing packages for in vivo assets. |
| Q4 2030 | 99.04 | +3.26% | +75.11% | Preparations for regulatory submissions and commercial manufacturing infrastructure for systemic in vivo assets cause minor margin digestion, keeping equity performance orderly heading into fiscal year-end. |
| Q1 2031 | 101.80 | +2.79% | +79.99% | Resolution of the convertible senior notes maturity via equity conversion eliminates debt repayment overhang. The clarified capital structure and diluted share count establish a stable foundation for long-term equity compounding. |
| Q2 2031 | 105.21 | +3.35% | +86.02% | Priority regulatory reviews for wholly owned systemic gene editing candidates expand addressable market visibility. The company establishes clear technical leadership across both ex vivo cell and in vivo genetic medicines. |
| Q3 2031 | 108.93 | +3.54% | +92.60% | Commercial launches for next-generation therapies alongside mature global Casgevy cash flows complete the transformation into a multi-product biopharmaceutical platform, securing strong terminal enterprise valuation. |
CRISPR Therapeutics is navigating a pivotal corporate evolution from an ex vivo cellular engineering pioneer into a diversified, multi-product genomic medicine platform. Market participants mischaracterize early CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry performance as a launch failure, failing to account for the structural eight-to-twelve-month lag inherent in autologous cell mobilization, quality validation, and myeloablative conditioning. As Qualified Treatment Centers scale globally and pediatric label expansions take effect, CRISPR's 40% net collaboration profit share will shift from an operational expense drag toward a positive cash flow stream. Concurrently, wholly owned systemic in vivo programs—principally CTX310 targeting ANGPTL3—are demonstrating durable multi-lipid knockdown in human clinical cohorts, validating non-viral lipid nanoparticle delivery and de-risking a cardiometabolic market orders of magnitude larger than rare hematology niches. Valuation sensitivity remains tightly linked to macroeconomic cost-of-capital pressures and clinical safety margins. Holding approximately $2.36 billion in cash, cash equivalents, and marketable securities provides a resilient multi-year operational runway, fully insulating development from distressed equity refinancing while the March 2031 convertible senior notes dictate prospective share-count dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry.
Key insights
- CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry accounting reflects a substantial lead-lag mismatch where over 500 patient initiations generate trailing collaboration revenue only after completing protracted conditioning protocols.
- In vivo hepatic editing transforms the platform from artisanal patient-specific transplant manufacturing into scalable, off-the-shelf outpatient infusions with superior gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry.
- Convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry obligations and heavy Phase 2/3 trial reinvestment consume liquidity, making non-dilutive biopharma partnerships essential to preserve equity ownership per share.
CRISPR Therapeutics is moving from lab research to commercial reality. Its approved gene therapy, CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry, takes several months to manufacture and requires difficult chemotherapy preparation, which has slowed early revenue. However, as specialized hospitals gain experience and younger patients become eligible, sales will ramp up. The company keeps 40% of the profits from its partner Vertex, which will gradually cover research costs. Meanwhile, its next-generation therapies aim to treat common heart conditions with simple, one-time injections rather than complex cell transplants. Backed by over $2.3 billion in cash, the company can fund its clinical trials for years without needing emergency loans.
Key insights
- Lengthy patient cell processing creates temporary revenue delays that hide strong underlying commercial demand from specialized hospitals.
- Wholly owned liver-editing programs offer much larger patient populations and cheaper manufacturing than personalized cell transplants.
- Pristine cash reserves eliminate bankruptcy danger, but advancing multiple clinical trials will require strict capital disciplinecapital disciplineA consistent practice of funding only investments expected to meet defined return and risk thresholds.View full glossary entry to avoid dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry.
Deep Dive
Prevailing market consensus views CRISPR Therapeutics as an uncommercialized clinical pioneer burdened by an agonizingly slow CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry rollout and an annual cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry approaching half a billion dollars. Investors dwell on busulfan conditioning toxicity, complex manufacturing cycles, and tight Medicaid budgets. High interest rates further penalize long-duration biotech pipelines, causing markets to treat in vivo assets as speculative lottery tickets.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus views CRISPR Therapeutics as an uncommercialized clinical pioneer burdened by an agonizingly slow CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry rollout and an annual cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry approaching half a billion dollars. Investors dwell on busulfan conditioning toxicity, complex manufacturing cycles, and tight Medicaid budgets. High interest rates further penalize long-duration biotech pipelines, causing markets to treat in vivo assets as speculative lottery tickets.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially underestimates the operational velocity of CRISPR's two-engine business model, creating an underpricing gap across its enterprise valueenterprise valueA measure of total business value, commonly calculated as equity value plus debt and preferred claims, less cash and cash equivalents.View full glossary entry. Market participants mistakenly extrapolate backward-looking collaboration revenue, ignoring that more than 500 patient initiations create a mechanical revenue ramp as cells complete processing. Crucially, investors assign near-zero option value to the wholly owned in vivo pipeline, where durable human proof-of-concept in ANGPTL3 silencing de-risks mass-market cardiometabolic indications.
Repricing Catalyst
What could make the market recognize and close that gap? Audited CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry global quarterly sales crossing $100 million in mid-2027 will decisively dispel commercial stagnation fears, triggering upward sell-side revisions. Simultaneously, Phase 1b clinical durability and safety data for wholly owned CTX310 in severe dyslipidemia will validate systemic liver editing. This dual confirmation will force institutional desks to revalue CRISPR from a niche ex vivo royalty holder to a multi-product biopharma compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Stabilization
Sentiment splits between value-focused caution regarding substantial operational cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry and visionary optimism surrounding in vivo clinical breakthroughs. This tension keeps volatility elevated as participants debate whether commercial revenues can outpace clinical expenditure before liquidity reserves decline.
Macro Regime Fit
Does the current market environment support the thesis? A restrictive monetary policy regime featuring Federal Reserve benchmark rates near 4.00% and 10-year Treasury yields around 5.0% acts as a persistent multiple-compression headwind for long-duration biotech assets. However, CRISPR's $2.36 billion liquid fortress insulates operations from hostile debt markets, generating significant non-operating interest income and decoupling clinical development from tight external capital conditions.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive disagreement across research perspectives centers on CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry's commercial cash conversion timeline and the valuation assigned to unapproved in vivo programs. Bearish frameworks argue that the 40/60 partnership structure absorbs initial cash flows through heavy commercial deductions, while toxic busulfan conditioning permanently caps patient throughput. Conversely, bullish perspectives assert that accrued apheresis starts will drive exponential revenue inflection by 2027, viewing CTX310's Phase 1a biomarker data as transformative platform validation. This tension will resolve as quarterly collaboration filings reveal whether net profit remittances turn positive before cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry depletes balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry reserves.
Base-Case Forces
Event Risk ScoreHigh75/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| In vivo hepatic editing clinical validation | Innovation And Product | +38% | +35% | Clinical proof-of-concept for CTX310 demonstrates durable ANGPTL3 silencing and substantial lipid reductions through one year in humans. Validating systemic lipid nanoparticle delivery bypasses complex cell manufacturing, unlocking massive cardiometabolic indications. This clinical progress expands terminal platform valuation as wholly owned assets advance toward registrational trials. |
| CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry commercial infusion acceleration inflection | Operational Efficiency | +32% | +55% | Authorized Treatment Centers are actively clearing logistical bottlenecks, converting accrued apheresis collections into completed patient infusions. Scaling global commercial volumes allows CRISPR's 40% net collaboration profit split to absorb fixed launch expenses, progressively transitioning the joint venture from an operational drag into dependable recurring cash flow. |
| Pediatric label expansion patient unlock | Regulatory | +22% | +35% | Regulatory clearance extending CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry to pediatric patients aged two to eleven meaningfully expands the eligible addressable population across North America and Europe. Treating pediatric populations before severe end-organ vascular damage accumulates aligns with payer lifetime-cost models, reinforcing multi-year volume compounding and expanding commercial royalty duration. |
| Fortress liquidity capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry moat | Capital Allocation | +18% | +15% | Maintaining approximately $2.36 billion in cash, cash equivalents, and marketable securities provides more than four years of clinical runway. In an elevated interest rate environment where competitors face distressed recapitalizations, this balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry strength fully funds clinical development, preserves equity ownership, and generates substantial non-operating interest income. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Myeloablative conditioning patient throughput bottleneck | Operational Efficiency | -24% | -35% | The mandatory requirement for toxic busulfan preconditioning causes severe hospitalization burdens, secondary malignancy risks, and infertility, creating substantial patient reluctance. This clinical friction caps real-world adoption to severe sickle cell crisis cases, prolonging commercialization timelines and delaying the partnership's transition toward high-margin volume profitability. |
| Substantial clinical pipeline cash absorption | Capital Allocation | -20% | -25% | CRISPR continues burning between $400 million and $500 million annually to advance preclinical and clinical pipelines across oncology, autoimmune, and cardiovascular diseases. Because the Vertex partnership nets commercialization outlays before distributing net profits, sustained negative free cash flowsfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry consume liquidity balances until commercial volumes achieve critical mass. |
| Macroeconomic rate regime discount drag | Macroeconomic And Macrofinancial | -16% | -8.0% | Elevated central bank benchmark rates near 4.0% and ten-year Treasury yields approaching 5.0% impose severe discount ratediscount rateThe rate used to convert future cash flows or values into present value.View full glossary entry headwinds on long-duration biotechnology valuations. High risk-free yieldsrisk free yieldsYields on instruments treated as having negligible default risk for a given currency and maturity.View full glossary entry disproportionately compress terminal multiplesterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry applied to distant clinical earnings, depressing trading valuations until recurring operational cash flows visibly cover corporate overhead. |
| Next generation gene editing competition | Competitive Positioning | -15% | -15% | Rival platforms developing base editingbase editingA precise gene-editing technology allowing single-nucleotide changes without inducing double-strand DNA breaks.View full glossary entry, prime editing, and epigenetic silencing aim to modify genomic targets without inducing double-strand DNA breaks. If competing non-cleaving technologies demonstrate superior clinical safety profiles or gentler delivery mechanisms, CRISPR's foundational Cas9 platform could face long-term pricing erosion and technological obsolescencetechnological obsolescenceThe risk that a product, asset, or capability loses economic usefulness because superior technology emerges.View full glossary entry. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Severe in vivo genomic toxicity halt | 22% | -50% | Emergence of dose-limiting hepatotoxicity, off-target mutagenesis, or oncogenic chromosomal translocations during Phase 2 trials of CTX310 would trigger an immediate FDA clinical hold by 2028. Such an adverse event would undermine the safety thesis of systemic lipid nanoparticle editing, collapsing CRISPR's platform valuation premium toward tangible liquidation valueliquidation valueThe estimated net value of a company's assets if it were to cease operations and sell everything.View full glossary entry. Rigorous guide-RNA optimization keeps this probability capped at 22%. |
| Sovereign healthcare reimbursement rationing caps | 28% | -35% | Intensifying fiscal deficits could compel Medicaid agencies and European single-payer authorities to impose strict spending caps or restrictive prior-authorization barriers on million-dollar therapies by late 2027. Inability to secure sustainable reimbursement frameworks would halve projected CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry peak sales, stranding treatment center infrastructure and entrenching collaboration deficits. This sovereign payer risk maintains a 28% probability under heightened government austerity. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Targeted non-myeloablative conditioning breakthrough validation | 30% | +65% | Successful Phase 2 validation of antibody-drug conjugate conditioning agents replacing toxic busulfan chemotherapy by late 2028 would eliminate fertility concerns and prolonged hospitalizations. Overcoming myeloablative toxicity would expand eligible CasgevycasgevyCasgevy is a branded gene-editing therapy name often used as shorthand for one-time genomic treatments targeting inherited disease mechanisms.View full glossary entry patient uptake fourfold across global markets. The probability remains at 30% due to developmental conditioning hurdles, yet success would permanently elevate peak commercial earnings power. |
| Major pharmaceutical in vivo licensing partnership | 32% | +55% | Compelling Phase 1b/2 clinical readouts for CTX310 in dyslipidemia could prompt a Tier-1 pharmaceutical giant to execute a multi-billion-dollar global co-development partnership by late 2027. An upfront cash injection exceeding $800 million would eradicate dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry risk and validate systemic in vivo editing economics. The event carries a 32% probability as management currently retains full proprietary control. |
Company Financial Analysis
CRISPR Therapeutics Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
CRISPR's financial statements reflect a major business transition. In fiscal 2025, revenue was just $3.51 million with an operating deficit of $568 million, as upfront partnership windfalls paused before Casgevy launched commercially. Trailing twelve-month revenue through mid-2026 reached $13.39 million, with second-quarter revenue inflecting to $10.18 million. Beneath these accounting losses, partner Vertex reported $76 million in second-quarter 2026 Casgevy sales. Because CRISPR splits commercial costs and profits 40/60, early revenues are offset by hospital launch expenses. As patient treatment volumes scale, collaboration revenue will begin overtaking research spending, gradually shrinking operational deficits.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 3.5M | USD -581.6M | USD -345.9M |
| 2024 | USD 35M | USD -366.3M | USD -144.7M |
| 2023 | USD 370M | USD -153.6M | USD -269.8M |
| 2022 | USD 436K | USD -650.2M | USD -532.9M |
| 2021 | USD 913.1M | USD 377.7M | USD 457.3M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | 15.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Reported profit margins currently look deeply negative because early commercial revenues are small relative to ongoing clinical trial expenses. Operating margins remain below negative 300%, reflecting the front-loaded costs of opening specialized treatment centers and enrolling patients. However, Casgevy carries a wholesale acquisition price of $2.2 million, which provides strong gross margin potential once fixed cell-processing costs are fully absorbed. As patient infusions expand, CRISPR's 40% net profit share will convert with high operational leverage. Furthermore, future off-the-shelf therapies will bypass individual cell manufacturing entirely, paving the way for significantly higher long-term operating margins.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -568.3M | -16191.4% | -16569.8% |
| 2024 | USD -466.6M | -1333.0% | -1046.4% |
| 2023 | USD -222.5M | -60.1% | -41.5% |
| 2022 | USD -673.2M | -154394.7% | -149122.7% |
| 2021 | USD 373.5M | 40.9% | 41.4% |
Balance sheet and leverage
AI Review
CRISPR maintains a fortress balance sheet that provides strong protection against market downturns. As of mid-2026, the company held approximately $2.36 billion in cash, cash equivalents, and marketable securities against $1.92 billion in equity. Gross debt-to-equity stands at a conservative 0.21, supported by an exceptional current ratio exceeding 13.0. This strong cash buffer was bolstered by $585 million in net proceeds from a convertible senior notes offering due in 2031. With over four years of operational runway at current spending rates, CRISPR avoids the immediate danger of bankruptcy or forced, dilutive stock offerings during periods of market stress.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 394.9M | USD 2B | USD 39.7M net debt | 13.32x |
| 2024 | USD 223.7M | USD 1.9B | USD 74.6M net cash | 22.07x |
| 2023 | USD 238.6M | USD 1.7B | USD 150.8M net cash | 17.54x |
| 2022 | USD 244M | USD 1.8B | USD 32.1M net debt | 15.30x |
| 2021 | USD 225M | USD 2.4B | USD 698M net cash | 20.17x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
CRISPR runs a capital-light business model, investing minimal money into physical buildings or heavy manufacturing equipment. In 2025, capital expenditures were just $0.91 million, while depreciation has hovered below $20 million annually. Instead, management directs nearly all capital into intellectual discovery, deploying $265 million into research and development in 2025 and roughly $65 million per quarter in 2026. Partner Vertex shoulders the vast majority of physical manufacturing facilities for Casgevy. This asset-light setup shields CRISPR from expensive factory overhead, focusing financial resources squarely on high-potential clinical trials for proprietary liver-editing and allogeneic cell therapies.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 914K | USD 265.3M |
| 2024 | USD 1.9M | USD 320.7M |
| 2023 | USD 9.5M | USD 387.3M |
| 2022 | USD 37.2M | USD 461.6M |
| 2021 | USD 81.7M | USD 438.6M |
Quarterly Forecast Scenarios
CRISPR Therapeutics Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $53.17 | $58.30 | $60.52 | $750.26 | |
| $48.91 | $60.18 | $64.75 | $736.44 | |
| $46.96 | $61.79 | $68.63 | $743.40 | |
| $44.61 | $65.26 | $74.71 | $755.15 | |
| $45.95 | $67.93 | $80.02 | $776.22 | |
| $45.03 | $70.23 | $83.22 | $787.13 | |
| $47.73 | $73.88 | $91.67 | $802.83 | |
| $49.64 | $77.69 | $97.17 | $812.05 | |
| $52.12 | $81.01 | $102.87 | $839.18 | |
| $53.68 | $83.72 | $108.04 | $850.50 | |
| $57.44 | $88.38 | $115.60 | $872.39 | |
| $59.74 | $92.21 | $128.31 | $885.51 | |
| $58.89 | $96.37 | $123.18 | $909.56 | |
| $61.24 | $99.97 | $133.04 | $916.13 | |
| $63.08 | $103.53 | $141.02 | $936.51 | |
| $61.82 | $108.53 | $152.30 | $947.34 | |
| $64.29 | $111.95 | $156.87 | $969.59 | |
| $65.58 | $115.80 | $167.85 | $979.99 | |
| $67.54 | $120.65 | $176.24 | $999.60 | |
| $66.87 | $125.00 | $183.29 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The analysis reveals high consensus on two foundational pillars: first, the fortress liquidity profile of approximately $2.36 billion in cash and marketable securities insulates near-term solvency against elevated interest rates; second, the commercialization of Casgevy is structurally encumbered by a six-to-twelve-month autologous vein-to-vein manufacturing cycle and busulfan conditioning toxicity. Reports attributing immediate exponential profitability are downweighted because CRISPR captures merely 40% of net joint program economics after Vertex deducts extensive commercialization overhead. Highest weights are assigned to rigorous frameworks identifying the gap between gross product sales and net collaboration distributions, while properly pricing the convertible note debt obligations maturing in 2031. Modest allocations are given to contrarian perspectives that penalize multi-year cash burn of roughly $450 million annually. This weighting balance reflects that platform value fundamentally hinges on translating in vivo hepatic biomarker durability into registrational clinical outcomes.
Universal Investor AI
The Polymath
GPT-6 AstraPresents exemplary evidentiary rigor grounded in SEC filings and primary clinical readouts. Its balanced probabilistic sum-of-the-parts framework avoids speculative exaggeration, appropriately capturing dilution and convertible debt obligations.
Universal Investor AI
The Polymath
Opus 5Offers an incisive breakdown separating cash value from pipeline option premiums. It accurately models the modest 40% collaboration capture and highlights the critical difference between biomarker endpoints and commercial outcomes.
Michael Burry AI
The Vulture
Gemini 3.8 FlashDelivers rigorous forensic accounting of the 40/60 partnership structure and highlights structural cash burn. This essential discipline anchors realistic valuation floors against uncritical commercial euphoria while properly accounting for convertible notes.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashRightfully challenges market complacency regarding autologous cell therapy bottlenecks and high discount rates. Its conservative cash burn projections provide a necessary counterbalance to exuberant clinical models.
Universal Investor AI
The Polymath
Gemini 3.8 FlashProvides sound operational integration linking Casgevy patient collection metrics to cash conversion cycles. However, its earnings ramp overlooks sustained R&D reinvestment needs across wholly owned clinical pipelines, requiring moderate weight calibration.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashEffectively analyzes balance sheet liquidity runway across macroeconomic cycles. The thesis balances ex vivo commercial gestation against in vivo pipeline optionality, supported by sound causal reasoning regarding cash burn absorption.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashCorrectly identifies the substantial lag between patient cell collection and recognized revenue. However, its multi-year margin expansion timeline slightly underestimates competitive pricing pressures from emerging genetic medicine platforms.
Universal Investor AI
The Polymath
Gemini 3.8 FlashAccurately diagnoses the prolonged vein-to-vein logistical drag of autologous therapy. However, its terminal multiple expansion assumptions appear overly optimistic given persistent macro discount rate pressures on developmental biotechnology.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashPresents thorough institutional access analysis, documenting the mechanics of state Medicaid contracting. It slightly downplays the operational friction of busulfan conditioning on real-world patient conversion velocity.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashExposes the institutional mechanisms of the CMS access model and pediatric volume expansion. Nevertheless, it minimizes trailing patent interference litigation costs and royalty stacking risks with competing academic estates.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashHighlights the commercial inflection across treatment centers and pediatric label approvals. However, its terminal multiple assumptions overlook potential off-target immunogenicity friction and rival base-editing advancements.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashArticulates the potential of commercial scale, but assumes near-monopoly pricing power and frictionless global reimbursement. This aggressive stance fails to account for statutory payer clawbacks and Medicaid spending caps.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashCaptures the strategic necessity of transitioning toward systemic in vivo delivery, but its intermediate price path extrapolates overly optimistic clinical de-risking velocity ahead of definitive Phase 2 human data.
Elon Musk AI
The Visionary
Gemini 3.8 FlashPresents a visionary assessment of programmable molecular medicine, but overstates near-term gross margin conversion while understating the capital intensity of large-scale cardiometabolic trials under restrictive rate environments.
Research Provenance
References & Context
This CRISPR Therapeutics consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 11 of 52 deduplicated sources retained for this batch.
- 01CGT (Cell and Gene Therapy Access) Model | CMScms.gov
- 02FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease | FDAfda.gov
- 0310-Qsec.gov
- 0431451___CLEANLPDF_LAN_14Apr202600431243_005.PDFsec.gov
- 05Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia | Arrowhead Pharmaceuticals, Inc.arrowheadpharma.com
- 06CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - BioSpacebiospace.com
- 07Vertex Pharmaceuticals | Vertex Reports Second Quarter 2026 Financial Resultsinvestors.vrtx.com
- 08CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 | CRISPR Therapeuticsir.crisprtx.com
- 09CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering | CRISPR Therapeuticsir.crisprtx.com
- 10CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | CRISPR Therapeuticsir.crisprtx.com
- 11CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | CRISPR Therapeuticsir.crisprtx.com
And 41 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.